Biomarkers Emerge as High-Growth Worldwide Market for Personalized Medicine

New York, January 16, 2007— With the advent of personalized medicine —therapies based on improved understanding of biological processes and data derived at the molecular level — biomarkers have become an essential coup for pharmaceutical researchers and developers alike. So important are they, that biomarkers may lead to a revolution in diagnostics for all categories of disease in the future, according to Biomarkers: A Market Briefing, the latest market research from Kalorama Information. Similarly, their increasing usage in drug development and clinical trials is expected to have an enormous impact on the success and effectiveness of future therapies.

Worldwide, the market for biomarkers in clinical trials is expected to jump from revenues of $427 million in 2006 to more than $1 billion in 2010. Similarly, on the diagnostics front, the global market for biomarkers for ovarian cancer which topped $175 million in 2006 is expected to surpass $328 million by 2010. Markets for stroke, cervical cancer, bladder cancer, and many other biomarkers are experiencing similar growth trends.

Their impact is just beginning to be felt. Biomarkers can not only increase the efficacy and reduce the risks associated with drug development, but they can also reduce the time and cost of Phase I and II clinical trials. Yet it’s at the patient level where biomarkers may have the most significant impact in the future.

“Most people are already familiar with c-reactive protein, a biomarker for inflammation in the blood which can help to identify individuals whose abnormal precancerous lesions will move closer to invasive lung cancer,” notes Joseph Constance, the report’s author. “This and other biomarkers foreshadow the future where biomarkers will become a key component to disease prevention and early diagnosis truly tailored to an individual based on one’s personal body chemistry and medical history.”

Biomarkers: A Market Briefing explains the types of biomarkers and applications as well as industry issues and trends. It includes U.S. and world revenues and forecasts in key diagnostic segments, discusses major products currently marketed, and profiles major industry players. It is available from Kalorama Information by visiting http://www.kaloramainformation.com/Biomarkers-Briefing-1059917. It is also available at MarketResearch.com.

About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent market research for the life sciences. For more information, contact Tom Ehart at 240-747-3014 or tehart@marketresearch.com, or visit www.KaloramaInformation.com.